Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.

This case report highlights two cases of alopecia areata in patients with celiac disease, noting the rare occurrence of one patient also having acquired hypertrichosis lanuginosa, which may be the first documented instance of this combination in the literature.

This case report describes a middle-aged man with alopecia universalis and ulcerative colitis, where hair regrowth occurred following treatment with azathioprine and mesalamine.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

In this case report, a 9-year-old boy with diffuse alopecia areata showed improvement with topical diphencyprone immunotherapy, suggesting it as a safe and effective treatment option in pediatric cases of alopecia areata resistant to other therapies.

This study found that a high sesquiterpene C. aeruginosa extract significantly reduced axillary hair growth in women compared to placebo with no apparent adverse effects.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

In this case report, a 44-year-old man with alopecia areata and seborrheic dermatitis experienced hair regrowth and reduced symptoms after treatment with intralesional corticosteroids, a combination cream, and loratadine, showing improvement within four weeks.

In this case report, a 60-year-old man with rheumatoid arthritis and sudden hair whitening was treated with baricitinib, showing significant hair repigmentation and regrowth in 8 months, suggesting potential for baricitinib in managing canities subita, especially when linked to alopecia areata.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

This study concluded that dermoscopy enhances the diagnostic capability for cicatricial alopecia beyond clinical inspection and identified novel dermoscopic features such as blue-grey dots.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

This case report describes a patient who developed alopecia after 18 weeks of treatment with dupilumab for atopic dermatitis.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

In this study, three patients with extensive alopecia areata receiving ustekinumab treatment showed significant hair regrowth and decreased inflammation over 20 weeks, suggesting potential targeted treatment for this condition.

This mouse study found that offspring of parents with uveitis showed increased susceptibility to experimental autoimmune uveitis, potentially due to altered immune and cellular processes.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

This report describes two cases where patients developed vitiligo as a side effect of diphencyprone treatment for alopecia areata, highlighting the need to inform patients about this potential adverse effect.

In this study, the researchers used a human hair follicle model to demonstrate that T cell stimulation can induce an alopecia areata–like phenotype, with cell proliferation and immune privilege collapse; however, the DHODH inhibitor farudodstat partially mitigated these effects by reducing T cell proliferation.

This article highlights a lack of published data on vitamin D deficiency prevalence among individuals with central centrifugal cicatricial alopecia, despite its known link to other forms of hair loss.

This study found that line-field confocal optical coherence tomography effectively visualized microscopic alterations in alopecia areata, suggesting its potential use in diagnosis and monitoring.

In this study, 16% of patients on dupilumab for atopic dermatitis experienced mild cutaneous adverse events, most commonly facial redness and psoriasis, leading to discontinuation in about 3% of cases.

This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

In this study, ustekinumab did not promote hair regrowth in human patients with alopecia areata or prevent disease development in an AA mouse model, suggesting limited efficacy for this treatment.

This study found that uric acid-linked microvascular dysfunction may play a role in alopecia areata, suggesting that targeting endothelial function and uric acid regulation could be a potential management strategy.